Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Extension to Study of Effects of Pomegranate Extract on Rising PSA Levels After Primary Therapy for Prostate Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Roll International Corporation
ClinicalTrials.gov Identifier:
NCT00732043
First received: August 7, 2008
Last updated: March 15, 2012
Last verified: March 2012
  Purpose

High concentrations of anti-oxidants in pomegranate seeds present a potential strategy to delay clinical prostate cancer progression and prolong the interval from primary treatment failure to hormonal ablation. This is a 48 month extension to the double-blind GUP-0205-1 study, to compare the effects of daily consumption of pomegranate liquid extract versus placebo on the absolute prostate-specific antigen (PSA) doubling time at the end of 12, 24, 36 and 48 months in male subjects who rolled-over from the GUP-0205-1 study.


Condition Intervention Phase
Prostate Cancer
Dietary Supplement: pomegranate extract
Dietary Supplement: pomegranate juice
Dietary Supplement: placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A 48-Month Extension to the Randomized, Double-blind, Placebo-Controlled Study of the Effects of Pomegranate Extract on Rising Prostate-Specific Antigen Levels in Men Following Primary Therapy for Prostate Cancer

Resource links provided by NLM:


Further study details as provided by Roll International Corporation:

Primary Outcome Measures:
  • The primary outcome variable will be the mean PSA doubling time at the end of 12, 24,36 and 48 months. [ Time Frame: 48 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • The mean change in PSA doubling time from baseline to end-of-treatment. [ Time Frame: 48 months ] [ Designated as safety issue: No ]
  • Response rates in positive and negative PSA doubling times with a clinically significant positive doubling time is defined as >150% of baseline. [ Time Frame: 48 months ] [ Designated as safety issue: No ]
  • Overall efficacy responses categorized as Objective Response, Progressive Disease, Stable Disease. [ Time Frame: 48 months ] [ Designated as safety issue: No ]
  • Measures of tolerability (adverse events) and toxicity (clinical chemistries, etc.). [ Time Frame: 48 months ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 200
Study Start Date: December 2007
Estimated Study Completion Date: January 2015
Estimated Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Dietary Supplement: pomegranate extract
8 oz per day, 48 months
Experimental: 2 Dietary Supplement: pomegranate juice
8 oz per day, 48 months
Other Name: PomWonderful
Placebo Comparator: 3 Dietary Supplement: placebo
8 oz per day, 48 months

Detailed Description:

The primary objectives are to compare the effects of daily consumption of pomegranate liquid extract versus placebo on the absolute prostate-specific antigen (PSA) doubling time at the end of 12,24, 36 and 48 months in male subjects who rolled-over from the GUP-0205-1 study. Secondary objectives are to determine the effect of the pomegranate treatment on the change in PSA doubling time from baseline to each 12-month visit, to determine the time to tumor recurrence, to assess the tolerability and toxicity of the pomegranate treatment and to determine the effect of the pomegranate treatment on response rates for positive PSA doubling times and for declining post-treatment PSA levels (negative doubling times).

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • No evidence of disease progression while on any of the three GUP-0205 study products (disease progression defined as > 100% increase in serum PSA [with a minimum value of 1.0 ng/mL]).
  • Willingness and ability to sign an informed consent document.
  • Agreement with complete abstinence from other commercially available pomegranate products during the course of the study.
  • Use of dietary/herbal supplements (e.g., saw palmetto, selenium, etc) is acceptable provided the dose has been stable during the course of the GUP-0205- 1 study.

Exclusion Criteria:

  • Significant concomitant medical or psychiatric condition that, in the opinion of the Principal Investigator, would put the subject at risk or compromise the protocol.
  • Hormonal therapy, with the exception of neoadjuvant androgen deprivation therapy (ADT) prior to or concurrent with primary therapy. Subjects who underwent neoadjuvant ADT cannot have a serum testosterone of ≤150 ng/mL at study entry.
  • Concomitant or antecedent hormonal therapy for rising serum PSA after initial therapy of prostate cancer.
  • Subjects unable or unwilling to comply with protocol requirements.
  • Prior treatment with experimental drugs, high dose steroids, or with any other cancer treatment within 4 weeks prior to the first dose of study product and for the duration of the study.
  • Serum PSA >7.0 ng/mL (assessed at termination of the double-blind study; at any PSA level, the subject will be excluded if determined by the Principal Investigator that the subject's continued participation would not be in their best interest).
  • Serum PSA doubling time <13 weeks (assessed at termination of the double-blind study).
  • Evidence of metastatic disease on physical examination or on CT or bone scan.
  • Use of finasteride, dutasteride at any point since primary therapy or during the study.
  • Clinically significant abnormal laboratory value greater than 2 times the upper limit of normal (>2XULN).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00732043

Locations
United States, California
UCLA School of Medicine
Los Angeles, California, United States, 90095-1738
Sponsors and Collaborators
Roll International Corporation
Investigators
Principal Investigator: Allan J Pantuck, MD University of California, Los Angeles
Principal Investigator: Arie S Belldegrun, MD University of California, Los Angeles
  More Information

No publications provided

Responsible Party: Roll International Corporation
ClinicalTrials.gov Identifier: NCT00732043     History of Changes
Other Study ID Numbers: GUP-0205-1XX
Study First Received: August 7, 2008
Last Updated: March 15, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Roll International Corporation:
prostate cancer
prostate-specific antigen
PSA
pomegranate

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms

ClinicalTrials.gov processed this record on November 27, 2014